専門家のコンセンサスに基づいた処方箋デジタル療法のための政策成熟度モデルの開発: eDelphi研究のためのプロトコル
João Rocha-Gomes1, Bernardo Sousa-Pinto2, Ana Luisa Neves2,3
1Faculty of Medicine, Department of Community Medicine, Health Information and Decision, University of Porto, Porto, Portugal jngomes@med.up.pt.
BMJ open
|February 15, 2026
まとめ
この研究は,処方箋デジタル療法薬 (PDTx) の準備度を評価するための政策成熟度枠組みを開発しています. eDelphiの研究は,これらのソフトウェアベースの健康ソリューションの一貫した採用を導くことを目的としています.
科学分野:
- デジタル・ヘルス・デジタル・ヘルス
- 保健政策 保健政策 保健政策
- ヘルスケア・イノベーション・ヘルスケア
背景:
- 処方箋デジタル療法 (PDTx) は,新しい治療ソリューションを提供しているが,政策の格差が分散している.
- 規制,払い戻し,統合の変動は,利害関係者にとって採用の不確実性を生み出します.
- PDTxに対する国家または地域の準備状態を評価するには,体系的なアプローチが必要である.
研究 の 目的:
- PDTxの採用準備度を評価するための包括的な政策成熟度フレームワークを開発し,検証する.
- 政策立案者,開発者,およびプロバイダーにPDTx実装の複雑さをナビゲートする上で指導するためです.
- 医療システムへのPDTxの統合を推進し,ベンチマークするためのコンセンサス主導のツールを確立する.
主な方法:
- 6つのステークホルダーグループのさまざまな専門家と3ラウンドまで参加したe-Delphiの研究.
- 欧州の専門家を優先する有意義なサンプリングで,より広範な国際的展望の可能性があります.
- 定量的なデータには5ポイントのライカート・スケール,定性的な洞察にはオープン・テキスト・プロンプトを使用し,コンセンサスは≥70%の合意と定義されています.
主要な成果:
- 研究プロトコルは,PDTxポリシーの成熟度フレームワークの反復的な精錬と検証を概説しています.
- フレームワークの領域,スコア付け基準,および成熟度の値に関するコンセンサスが達成されます.
- 検証されたフレームワークは,PDTx政策の策定と実施に不可欠な要素を把握します.
結論:
- 開発されたフレームワークは,PDTxの採用を評価し,前進させるための参照を提供します.
- それは,不確実性を軽減し,司法管轄全域で一貫した政策開発を促進することを目的としています.
- 出版物や政策書簡を通じて普及させることで,デジタル・ヘルス・ガバナンスを支援します.
関連する概念動画
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
17
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
17
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
17
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
17
Pharmacodynamic Models: Overview
19
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
19
Drug Administration and Therapy Phases: Overview
1.5K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.5K
Pharmacokinetic–Pharmacodynamic Relationship: Problems
18
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
18
Pharmacodynamic Models: Linear Concentration–Effect Model
20
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
20


